Cargando…

Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry

BACKGROUND: The direct factor Xa inhibitor rivaroxaban is approved for the treatment of venous thromboembolism (VTE), based on the results of large phase III trials. OBJECTIVES: To confirm rivaroxaban's effectiveness and safety in routine clinical care of patients with VTE. METHODS: Data were o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Stephanie, Tittl, Luise, Speed, Victoria, Roberts, Lara, Patel, Jignesh, Patel, Raj, Arya, Roopen, Kucher, Nils, Spirk, David, Sahin, Kurtulus, Beyer‐Westendorf, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618466/ https://www.ncbi.nlm.nih.gov/pubmed/36324830 http://dx.doi.org/10.1002/rth2.12829

Ejemplares similares

Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry
por: Beyer-Westendorf, Jan, et al.
Publicado: (2021)

Periinterventional Management of Edoxaban in Major Procedures: Results from the DRESDEN NOAC REGISTRY
por: Köhler, Christina, et al.
Publicado: (2023)

Drug persistence with rivaroxaban therapy in atrial fibrillation patients—results from the Dresden non-interventional oral anticoagulation registry
por: Beyer-Westendorf, Jan, et al.
Publicado: (2015)

Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry
por: Speed, Victoria, et al.
Publicado: (2021)

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Speed, Victoria, et al.
Publicado: (2021)

Role of age, sex, and specific provoking factors on the distal versus proximal presentation of first symptomatic deep vein thrombosis: analysis of the SWIss Venous ThromboEmbolism Registry (SWIVTER)
por: Spirk, David, et al.
Publicado: (2021)

The impact of body weight on rivaroxaban pharmacokinetics
por: Barsam, Sarah J., et al.
Publicado: (2017)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
por: Beyer-Westendorf, Jan, et al.
Publicado: (2019)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs
por: Altman, Raul, et al.
Publicado: (2014)

Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice
por: Beyer-Westendorf, Jan, et al.
Publicado: (2017)

Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill
por: Brenner, Benjamin, et al.
Publicado: (2019)

Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in at-risk patient groups: pregnancy, elderly and obese patients
por: Brenner, Benjamin, et al.
Publicado: (2019)

Traditional Anticoagulants and Hair Loss: A Role for Direct Oral Anticoagulants? A Review of the Literature
por: Watras, Magdalena M., et al.
Publicado: (2016)

Dresden concerti,
por: Vivaldi, Antonio, 1678-1741
Publicado: (1997)

Factors influencing the recruitment of lactating women in a clinical trial involving direct oral anticoagulants: a qualitative study
por: Zhao, Yating, et al.
Publicado: (2018)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study
por: Cohen, Alexander T., et al.
Publicado: (2018)

Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation – Data from the Ljubljana Registry
por: Vene, Nina, et al.
Publicado: (2016)

Lack of reversibility for NOACs
por: Al-Kindi, Sadeer
Publicado: (2014)

TAVR: nemesis of NOACs?
por: Polzin, Amin, et al.
Publicado: (2022)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis
por: Costa, Olivia S., et al.
Publicado: (2020)

Accelerators come into focus in Dresden
Publicado: (2014)

Mode of Delivery Does Not Influence Postpartum Hypercoagulability Measured by Thrombin Generation or Thromboelastometry
por: Guimicheva, Boriana, et al.
Publicado: (2020)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Nine-Year Trends in Prevention of Thromboembolic Complications in Elderly Patients with Atrial Fibrillation Treated with NOACs
por: Bielecka, Bernadetta, et al.
Publicado: (2022)

Prospective Registry of Rivaroxaban Management of Cancer-Associated Venous Throboembolism (PRIMECAST) Study
por: Tamura, Yuichi, et al.
Publicado: (2019)

The Dresden Protocol for Multidimensional Walking Assessment (DMWA) in Clinical Practice
por: Trentzsch, Katrin, et al.
Publicado: (2020)

Current Status of the Korean Venous Thromboembolism Registry
por: Oh, Doyeun
Publicado: (2011)

Dresden concerti. RV 170, 314a, 319, 341, 366 & 383 /
por: Vivaldi, Antonio, 1678-1741
Publicado: (1997)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry
por: Kepka, Sabrina, et al.
Publicado: (2023)

Response to ‘Lack of reversibility for NOACs’
por: Kaba, Riyaz A, et al.
Publicado: (2014)

How do anticoagulants impact menstrual bleeding and quality of life? - The PERIOD study
por: Patel, Jignesh P., et al.
Publicado: (2023)

Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic
por: Patel, Rachna, et al.
Publicado: (2021)

Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry
por: Renda, Giulia, et al.
Publicado: (2020)

Do Patients with Atrial Fibrillation and a History of Ischemic Stroke Overuse Reduced Doses of NOACs?—Results of the Polish Atrial Fibrillation (POL-AF) Registry
por: Szyszkowska, Anna, et al.
Publicado: (2022)

Clinical epidemiology of venous thromboembolic disease: An institutional registry
por: AlSheef, Mohammed, et al.
Publicado: (2022)

Venous thromboembolism in patients with cancer: design and rationale of a multicentre, prospective registry (Cancer-VTE Registry)
por: Ohashi, Yasuo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3v4eclutbg7htdig164u1nihlv